ORLANDO, Fla., Feb. 24 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the "Company" or "Telzuit") (BULLETIN BOARD: TZMTE) expects to file its Quarterly Report on Form 10-QSB for the quarter ended December 31, 2005 on or about March 3, 2006, and anticipates that NASDAQ will remove the letter "E" from the Company's stock symbol at that time. The Company filed a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission on February 14, 2006 to afford the Company additional time to deliver information in response to inquiries from its independent accountants to ensure the accuracy and completeness of the Company's Form 10-QSB. The Company's internal and external accountants are working diligently on completing the Company's financial statements.
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The first step in this mission will initially take the form of our state-of-the-art, FDA approved, Bio-Patch Wireless Heart Monitor. This is a full 12-lead, completely wireless, Holter monitor, which is new to the marketplace. Telzuit is also building its own dedicated intranet as a platform to handle several of the products it will be releasing, including its initial product, the Bio-Patch Wireless Heart Monitor. More information on Telzuit, its business model, and its products can be found on its website: http://www.telzuit.com/, or by calling 407-354-1222.
Forward Looking Statement:
Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward looking statements speak only as of the date of this release, and Telzuit undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contacts:
Telzuit Medical Technologies, Inc., Orlando
James Tolan, Senior VP
407-354-1222
Brainerd Communicators, Inc.
Jennifer Gery (press)
Todd St. Onge (investors)
212-986-6667
First Call Analyst:
FCMN Contact:
